CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

Broker Recommendations Charles River Laboratories International, Inc. Berne S.E.

Stocks

RV6

US1598641074

Biotechnology & Medical Research

End-of-day quote Berne S.E. 2026-08-28			5-day change	1st Jan Change
237.04 ^CHF	-2.17%		-0.36%	-

08-20	Charles River Laboratories International Insider Sold Shares Worth $599,711, According to a Recent SEC Filing	MT
08-20	Charles River, Medigen Partner on Multivalent Enterovirus Vaccine	MT

Broker Recommendations

08-10	TD Cowen Adjusts PT on Charles River Laboratories International to $300 From $235, Maintains Buy Rating	MT
08-10	Rothschild & Co Redburn Adjusts PT on Charles River Laboratories International to $318 From $241, Maintains Buy Rating	MT
08-06	Barclays Adjusts Price Target on Charles River Laboratories International to $300 From $220	MT
08-06	RBC Adjusts PT on Charles River Laboratories International to $282 From $215, Keeps Outperform Rating	MT
08-06	Deutsche Bank Adjusts Charles River Laboratories International PT to $300 From $260, Maintains Buy Rating	MT
08-06	JPMorgan Upgrades Charles River Laboratories International to Overweight From Neutral, Adjusts PT to $310 From $180	MT
07-13	BofA Adjusts Price Target on Charles River Laboratories International to $264 From $220	MT
07-13	Baird Adjusts Charles River Laboratories International Price Target to $255 From $213, Maintains Outperform Rating	MT
07-13	Mizuho Adjusts Price Target on Charles River Laboratories International to $230 From $192, Maintains Neutral Rating	MT
07-09	Morgan Stanley Adjusts Price Target on Charles River Laboratories International to $260 From $220	MT
07-07	Evercore ISI Adjusts Price Target on Charles River Laboratories International to $260 From $220	MT
07-01	Argus Raises Price Target on Charles River Laboratories International to $250 From $200, Maintains Buy Rating	MT
06-18	Rothschild & Co Redburn Adjusts Charles River Laboratories International PT to $241 From $230, Maintains Buy Rating	MT
06-17	Charles River Laboratories Shares Rise After Morgan Stanley Upgrade	MT
06-17	Morgan Stanley Upgrades Charles River Laboratories International to Overweight From Equal Weight, Adjusts PT to $220 From $185	MT
06-05	Charles River Laboratories Has Potential to Outperform in 2H 2026, RBC Says	MT
04-14	Charles River Laboratories Positioned as 'Leading' CRO as Preclinical R&D Inflection Nears, RBC Says	MT
04-14	Barclays Adjusts Price Target on Charles River Laboratories International to $210 From $200, Maintains Overweight Rating	MT
04-14	RBC Initiates Charles River Laboratories International at Outperform With $215 Price Target	MT
04-08	Baird Raises Price Target on Charles River Laboratories International to $200 From $197, Maintains Outperform Rating	MT
03-09	Baird Adjusts Price Target on Charles River Laboratories International to $197 From $193	MT
02-25	UBS Adjusts Price Target on Charles River Laboratories International to $175 From $170, Maintains Neutral Rating	MT
02-20	Rothschild & Co Redburn Adjusts Charles River Laboratories PT to $200 From $211, Maintains Buy Rating	MT
02-20	Mizuho Securities Adjusts Charles River Laboratories Price Target to $175 From $215, Maintains Neutral Rating	MT
02-20	TD Cowen Adjusts Price Target on Charles River Laboratories International to $235 From $251, Maintains Buy Rating	MT